Chest Radiation in Childhood a Risk Factor for Breast Cancer in Adult Women

Surviving childhood cancer may only be the beginning for women whose treatment included chest radiotherapy, a new study shows.

According to findings reported online in the Journal of Clinical Oncology by Chaya S. Moskowitz, PhD, of Memorial Sloan-Kettering Cancer Center and colleagues, these women have a breast cancer risk that is 20 times higher than women without such a history in the general population.

It gets worse: Of the women who do go on to develop breast cancer, as many as one fifth of them die of the disease within 10 years of diagnosis, a figure that is double that of women with newly diagnosed breast cancer.

Researchers studied 1,230 female survivors of childhood cancer who had been treated with chest radiotherapy. Among 1230 average women, researchers would expect to find between 9 and 10 cases of breast cancer, but among this cohort they found 203 cases.

"Those treated with whole-lung irradiation have a greater risk of breast cancer than previously recognized, demonstrating the importance of radiation volume," they wrote. "Importantly, mortality associated with breast cancer after childhood cancer is substantial."

They found that the median time from diagnosis of childhood cancer to the onset of breast cancer was 23 years. The median age at breast cancer diagnosis was 39.

Typically, survivors of Hodgkin's lymphoma have had a high risk of breast cancer later in life because of the established use of chest irradiation in treating that disease. In fact, researchers noted that "the cumulative breast cancer risk is remarkably similar between BRCA1 carriers and Hodgkin lymphoma survivors."

They pressed for providing women who received chest irradiation for childhood cancer "a model of care involving risk communication and counseling, breast cancer surveillance, and prevention strategies" similar to that used with women who have a high familial risk of breast cancer.

Source: MedPage Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap